APELLIS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.52 USD | +0.52% |
|
-10.47% | -28.97% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 822M | Sales 2025 * | 1.22B | Capitalization | 5.13B |
|---|---|---|---|---|---|
| Net income 2024 * | -136M | Net income 2025 * | 145M | EV / Sales 2024 * | 5.86 x |
| Net cash position 2024 * | 317M | Net cash position 2025 * | 646M | EV / Sales 2025 * | 3.69 x |
| P/E ratio 2024 * |
-38.9
x | P/E ratio 2025 * |
38.9
x | Employees | 704 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.86% |
More Fundamentals
* Assessed data
More news
Latest transcript on Apellis Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 day | +0.52% | ||
| 1 week | -10.47% | ||
| Current month | -3.78% | ||
| 1 month | -22.86% | ||
| 3 months | -37.98% | ||
| 6 months | -8.28% | ||
| Current year | -28.97% |
1 week
41.57
49.06
1 month
38.2257.85
Current year
38.2273.80
1 year
19.8394.75
3 years
19.8394.75
5 years
16.8594.75
10 years
11.4594.75
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 54 | 09-09-24 | |
Cedric Francois
FOU | Founder | 51 | 09-09-24 |
Timothy Sullivan
DFI | Director of Finance/CFO | 53 | 17-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alec Machiels
FOU | Founder | 51 | 09-09-24 |
| Director/Board Member | 65 | 13-06-30 | |
Andrew Dunlop
BRD | Director/Board Member | 52 | 10-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.61% | 0 M€ | 0.00% | - | |
| 0.45% | 0 M€ | 0.00% | - | |
| 0.19% | 4 M€ | +20.15% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 42.52 | +0.52% | 1,052,629 |
| 24-05-08 | 42.3 | -3.64% | 2,160,470 |
| 24-05-07 | 43.9 | -10.06% | 4,519,000 |
| 24-05-06 | 48.81 | +2.84% | 1,849,993 |
| 24-05-03 | 47.46 | -0.06% | 1,106,943 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotes
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Companyâs approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
42.3
USD
Average target price
80.38
USD
Spread / Average Target
+90.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.97% | 5.13B | |
| -2.72% | 88.91B | |
| +2.76% | 41.25B | |
| -13.92% | 31.99B | |
| +50.51% | 24.73B | |
| -15.25% | 15.54B | |
| -39.93% | 12.07B | |
| -9.08% | 12.05B | |
| -14.80% | 12.02B | |
| +6.22% | 8.84B |
- Stock Market
- Equities
- APLS Stock